---
title: "The international president of Eli Lilly stated that the company is replicating its consumer-centere"
description: "The international president of Eli Lilly stated that the company is replicating its consumer-centered obesity treatment strategy in countries and regions such as the UK, China, UAE, and Australia"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/257670066.md"
published_at: "2025-09-17T07:24:19.000Z"
---

# The international president of Eli Lilly stated that the company is replicating its consumer-centere

> The international president of Eli Lilly stated that the company is replicating its consumer-centered obesity treatment strategy in countries and regions such as the UK, China, UAE, and Australia

The international president of Eli Lilly stated that the company is replicating its consumer-centered obesity treatment strategy in countries and regions such as the UK, China, the UAE, and Australia

### Related Stocks

- [LLY.US - Eli Lilly](https://longbridge.com/en/quote/LLY.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| 禮來公司（LLY）建立了價值 15 億美元的減肥藥庫存 | 禮來（LLY）已準備好 15 億美元的庫存，以迎接其新減肥藥 Orforglipron 預計在四月獲得 FDA 批准。該公司計劃在今夏推出該藥，並進行大規模的營銷活動，以與諾和諾德的 Wegovy 競爭。分析師對禮來的股票給予了一致的強烈買 | [Link](https://longbridge.com/en/news/276070062.md) |
| 禮來公司在克羅恩病治療領域取得了新的突破 | 禮來（Eli Lilly，股票代碼：LLY）宣佈其克羅恩病治療藥物 Omvoh 的第三階段重要結果，超過 90% 的患者實現了三年無類固醇緩解。VIVID-2 研究顯示，臨牀緩解率為 92.4%，無類固醇緩解率為 91.2%。Omvoh 還 | [Link](https://longbridge.com/en/news/276442344.md) |
| 禮來公司 $LLY 的股票被 Assetmark Inc. 收購 | Assetmark Inc. 在第三季度將其在禮來的持股增加了 6.0%，目前持有 55,360 股，價值為 4224 萬美元。其他機構投資者也增持了股份，82.53% 的股票由對沖基金持有。禮來的股票開盤價為 1,040.12 美元，市值 | [Link](https://longbridge.com/en/news/275971336.md) |
| 禮來公司的一種實驗性抗癌藥物降低了早期肺癌患者的復發風險 | 禮來的第三階段 LIBRETTO-432 試驗顯示，Retevmo（selpercatinib）在早期非小細胞肺癌患者中顯著降低了復發風險。該試驗招募了 151 名患者，並顯示出改善的無事件生存期。過去一年，禮來股票上漲了 21.33%，交 | [Link](https://longbridge.com/en/news/276119494.md) |
| 諾和諾德公司通過獲得歐洲更高劑量的批准，擴大了注射用 Wegovy 的供應 | 諾和諾德公司已獲得歐洲委員會批准，推出其肥胖治療藥物 Wegovy 的新劑量 7.2mg，允許成年人直接從 2.4mg 劑量過渡。該更高劑量通過三次 2.4mg 注射給藥，旨在增強減重效果，試驗顯示體重減少 21%。此次批准是在歐洲藥品管理 | [Link](https://longbridge.com/en/news/276254123.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.